Literature DB >> 7202476

Skeletal muscle digoxin concentration and its relation to serum digoxin concentration and cardiac effect in healthy man.

T Jogestrand, K Sundqvist.   

Abstract

Blood samples and skeletal muscle biopsies (m. quadriceps femoris, vastus lateralis) were taken from seven healthy subjects for analysis of serum and skeletal muscle digoxin concentrations by radioimmunoassay using a percutaneous needle biopsy technique for muscle sampling. The subjects were investigated on two digoxin dose levels and on the third day after withdrawal of digoxin. It was found that the skeletal muscle/serum digoxin ratio was significantly higher than the corresponding ratio obtained in a previous study with muscle sampling (m. rectus abdominis) from patients during open heart surgery. The present study indicates a significant correlation between the digoxin concentrations in serum and skeletal muscle as well as between cardiac effect, measured by changes in QS2I, and skeletal muscle digoxin concentration. A doubling of the digoxin dose gave a proportional increase in skeletal muscle digoxin concentration. The magnitude of the estimated half-life of skeletal muscle digoxin was the same as previously reported for serum or plasma digoxin.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7202476     DOI: 10.1007/bf00568394

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  34 in total

1.  THE EFFECT OF DESLANOSIDE ON THE DURATION OF THE PHASES OF VENTRICULAR SYSTOLE IN MAN.

Authors:  A M WEISSLER; A R KAMEN; R S BORNSTEIN; C D SCHOENFELD; S COHEN
Journal:  Am J Cardiol       Date:  1965-02       Impact factor: 2.778

2.  Histochemical and biochemical changes in human skeletal muscle with age in sedentary males, age 22--65 years.

Authors:  L Larsson; B Sjödin; J Karlsson
Journal:  Acta Physiol Scand       Date:  1978-05

3.  Dose-independent pharmacokinetics of digoxin in humans.

Authors:  H R Ochs; D J Greenblatt; G Bodem; J S Harmatz
Journal:  Am Heart J       Date:  1978-10       Impact factor: 4.749

4.  Myocardial distribution of digoxin and renal function.

Authors:  W J Jusko; M Weintraub
Journal:  Clin Pharmacol Ther       Date:  1974-09       Impact factor: 6.875

5.  Determination of therapeutic and toxic serum digoxin concentrations by radioimmunoassay.

Authors:  T W Smith; V P Butler; E Haber
Journal:  N Engl J Med       Date:  1969-11-27       Impact factor: 91.245

6.  The distribution and excretion of tritiated substances in experimental animals following the administration of digoxin-3H.

Authors:  C E Harrison; R O Brandenburg; P A Ongley; A L Orvis; C A Owen
Journal:  J Lab Clin Med       Date:  1966-05

7.  Dose-response relation between therapeutic levels of serum digoxin and systolic time intervals.

Authors:  R J Hoeschen; T E Cuddy
Journal:  Am J Cardiol       Date:  1975-04       Impact factor: 2.778

8.  Digoxin concentration in right atrial myocardium, skeletal muscle and serum in man: influence of atrial rhythm.

Authors:  T Jogestrand
Journal:  Eur J Clin Pharmacol       Date:  1980-04       Impact factor: 2.953

9.  Relationship between plasma concentration and dose of digoxin in patients with and without renal impairment.

Authors:  R D Okada; W D Hager; P E Graves; M Mayersohn; D G Perrier; F I Marcus
Journal:  Circulation       Date:  1978-12       Impact factor: 29.690

10.  [Fibre type and glycoside concentrations of human skeletal muscle (author's transl)].

Authors:  H D Bundschu; R Haasis; D Larbig
Journal:  Experientia       Date:  1977-03-15
View more
  8 in total

1.  Physical exercise and digoxin binding to skeletal muscle: relation to exercise intensity.

Authors:  T Joreteg; T Jogestrand
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

2.  Physical exercise and binding of digoxin to skeletal muscle--effect of muscle activation frequency.

Authors:  T Joreteg; T Jogestrand
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  Skeletal muscle digoxin binding in patients with renal failure.

Authors:  T Jogestrand; F Ericsson
Journal:  Br J Clin Pharmacol       Date:  1983-07       Impact factor: 4.335

4.  Skeletal muscle digoxin concentration during digitalization and during withdrawal of digoxin treatment.

Authors:  T Jogestrand; F Ericsson; K Sundqvist
Journal:  Eur J Clin Pharmacol       Date:  1981-01       Impact factor: 2.953

5.  Effect of salbutamol on digoxin pharmacokinetics.

Authors:  M Edner; T Jogestrand; R Dahlqvist
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

6.  Skeletal muscle binding and renal excretion of digoxin in man.

Authors:  K Schenck-Gustafsson; T Jogestrand; R Dahlqvist
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Quinidine-induced changes in serum and skeletal muscle digoxin concentration; evidence of saturable binding of digoxin to skeletal muscle.

Authors:  T Jogestrand; K Schenck-Gustafsson; R Nordlander; R Dahlqvist
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

8.  Oral digoxin effects on exercise performance, K+ regulation and skeletal muscle Na+ ,K+ -ATPase in healthy humans.

Authors:  Simon Sostaric; Aaron C Petersen; Craig A Goodman; Xiaofei Gong; Tai-Juan Aw; Malcolm J Brown; Andrew Garnham; Collene H Steward; Kate T Murphy; Kate A Carey; James Leppik; Steve F Fraser; David Cameron-Smith; Henry Krum; Rodney J Snow; Michael J McKenna
Journal:  J Physiol       Date:  2022-08-02       Impact factor: 6.228

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.